Pacira BioSciences (PCRX) to Release Earnings on Wednesday

Pacira BioSciences (NASDAQ:PCRX) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.72 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Pacira BioSciences Trading Up 4.7 %

Shares of NASDAQ PCRX traded up $0.77 during midday trading on Tuesday, reaching $17.22. 176,244 shares of the stock were exchanged, compared to its average volume of 862,949. The stock has a 50 day moving average price of $15.43 and a 200-day moving average price of $21.18. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $794.36 million, a P/E ratio of 12.56 and a beta of 0.82. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $35.95.

Insider Activity at Pacira BioSciences

In related news, CEO Frank D. Lee purchased 8,264 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have purchased 11,176 shares of company stock worth $136,240. 6.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Needham & Company LLC decreased their price target on Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Royal Bank of Canada raised their target price on shares of Pacira BioSciences from $14.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Friday, October 4th. Finally, HC Wainwright dropped their price target on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $24.20.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.